Nissay Asset Management Corp Japan ADV Cuts Holdings in DexCom, Inc. (NASDAQ:DXCM)

Nissay Asset Management Corp Japan ADV reduced its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 12.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 88,578 shares of the medical device company's stock after selling 12,956 shares during the period. Nissay Asset Management Corp Japan ADV's holdings in DexCom were worth $7,107,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Forvis Mazars Wealth Advisors LLC boosted its position in shares of DexCom by 0.7% during the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock valued at $1,359,000 after purchasing an additional 118 shares in the last quarter. Principal Securities Inc. lifted its holdings in shares of DexCom by 3.4% during the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock valued at $316,000 after purchasing an additional 135 shares in the last quarter. Larson Financial Group LLC lifted its holdings in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the period. Level Four Advisory Services LLC lifted its holdings in DexCom by 1.1% in the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after acquiring an additional 150 shares during the period. Finally, Covestor Ltd lifted its holdings in DexCom by 15.6% in the fourth quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock valued at $86,000 after acquiring an additional 150 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Jereme M. Sylvain sold 7,000 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $73.83, for a total value of $516,810.00. Following the sale, the executive vice president now owns 135,482 shares in the company, valued at $10,002,636.06. This represents a 4.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares in the company, valued at approximately $26,183,401.02. This represents a 8.03% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 66,926 shares of company stock valued at $4,734,384. Insiders own 0.32% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on DXCM. Robert W. Baird cut their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Mizuho assumed coverage on DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective for the company. Canaccord Genuity Group raised their price target on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Cfra Research upgraded shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Finally, Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and lifted their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $98.11.

DexCom Trading Up 1.7%

Shares of NASDAQ DXCM traded up $1.48 during trading on Monday, reaching $86.96. The stock had a trading volume of 2,366,347 shares, compared to its average volume of 4,356,666. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $132.09. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The business's 50-day moving average price is $72.01 and its 200-day moving average price is $77.69. The company has a market cap of $34.10 billion, a P/E ratio of 60.81, a PEG ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company's revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter last year, the business posted $0.32 earnings per share. On average, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.